CORDIS
EU research results

CORDIS

English EN

Pathways common to brain development and ageing: defining strategies for preventive therapy and diagnostics

Objective

The increasing number of elderly people will have a major impact on the prevalence of age-related diseases, which will pose major challenges to keep health systems in Europe sustainable. Current knowledge is insufficient to identify the transition of normal brain ageing into Alzheimer`s Disease (AD)-like brain damage. Elucidation of the genes and pathways contributing to the earliest stages of AD pathology and associated neurodegeneration should be instrumental to allow intervention when the condition is still reversible. The aim of the DEVELAGE project is to characterise shared molecular pathways between early developmental processes in the brain and brain ageing. Our concept is based on the hypothesis that disorders of neural development contribute to age-related neurodegeneration, that developmentally essential proteins might have a role in neurodegeneration, and that neurodegeneration-related proteins and genes are important during the development of the brain. The DEVELAGE approach is unique in that it is brain tissue-based, derived from neuropathological diagnosis with detailed molecular analysis of the spectrum of developmental and ageing changes in the very same brain samples used for a comprehensive array of investigations in humans as well as in experimental models at genetic, epigenetic, transcription and protein levels. DEVELAGE contributes to the understanding of biological variation by examining relevant number of cases with different phases of ageing and neurodegeneration as well as developing brains with or without developmental disorders. Pathways examined in humans will be validated in animal models, including a non-human primate, and vice versa. The combination of human samples and animal models susceptible to experimental manipulation will promote the translation of clinically relevant data into experimentally testable predictions and promotes the exploitation of therapeutically relevant targets to reverse or halt disease progresssion.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

MEDIZINISCHE UNIVERSITAET WIEN

Address

Spitalgasse 23
1090 Wien

Austria

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 632 040

Administrative Contact

Gabor Geza Kovacs (Dr.)

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

Spain

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 333 600

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA

Italy

EU Contribution

€ 404 320

STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 342 000

UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES

France

EU Contribution

€ 327 885

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 337 080

BIOLUTION GMBH

Austria

EU Contribution

€ 268 360

INSTITUT CATALA DE LA SALUT

Spain

EU Contribution

€ 348 852

Project information

Grant agreement ID: 278486

Status

Closed project

  • Start date

    1 January 2012

  • End date

    31 December 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 881 830,13

  • EU contribution

    € 2 994 137

Coordinated by:

MEDIZINISCHE UNIVERSITAET WIEN

Austria